These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 3082277)

  • 21. Determination of anthracycline purity in patient samples and identification of in vitro chemical reduction products by application of a multi-diode array high-speed spectrophotometric detector.
    Cummings J; Morrison JG; Willmott N
    J Chromatogr; 1986 Sep; 381(2):373-84. PubMed ID: 3463565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intracellular accumulation, retention, and distribution of anthracyclines in a multidrug-resistant variant K562r].
    Hu X; Chen WY
    Zhongguo Yao Li Xue Bao; 1994 May; 15(3):275-9. PubMed ID: 7976387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetic study of methotrexate and the anthracyclines].
    Lokiec F; Najean Y; Kadouche J
    Nouv Rev Fr Hematol (1978); 1979; Suppl():XXXV. PubMed ID: 296375
    [No Abstract]   [Full Text] [Related]  

  • 24. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of fluorescence by anthracycline antibiotics: effects of xanthine oxidase and identification of the nonfluorescent metabolites.
    Dodion P; Bernstein AL; Fox BM; Bachur NR
    Cancer Res; 1987 Feb; 47(4):1036-9. PubMed ID: 3467841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines.
    Krishan A; Ganapathi R
    Cancer Res; 1980 Nov; 40(11):3895-900. PubMed ID: 6937236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
    Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
    Hurteloup P; Ganzina F
    Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspects of the chemical stability of doxorubicin and seven other anthracyclines in acidic solution.
    Beijnen JH; Wiese G; Underberg WJ
    Pharm Weekbl Sci; 1985 Jun; 7(3):109-16. PubMed ID: 3860797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of doxorubicin, daunorubicin and epirubicin in human and rat hepatoma cells.
    Le Bot MA; Glaise D; Kernaleguen D; Ratanasavanh D; Carlhant D; Riche C; Guillouzo A
    Pharmacol Res; 1991 Oct; 24(3):243-52. PubMed ID: 1659695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma.
    Fogli S; Danesi R; Innocenti F; Di Paolo A; Bocci G; Barbara C; Del Tacca M
    Ther Drug Monit; 1999 Jun; 21(3):367-75. PubMed ID: 10365655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance.
    Hindenburg AA; Baker MA; Gleyzer E; Stewart VJ; Case N; Taub RN
    Cancer Res; 1987 Mar; 47(5):1421-5. PubMed ID: 3469017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of anthracycline antitumor agents in four infusion fluids.
    Poochikian GK; Cradock JC; Flora KP
    Am J Hosp Pharm; 1981 Apr; 38(4):483-6. PubMed ID: 6945043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uptake kinetics and intracellular distribution of anthracyclines studied by laser cytofluorometry.
    Prosperi E; Croce AC; Bottiroli G; Dasdia T; Supino R
    Basic Appl Histochem; 1983; 27(2):117-27. PubMed ID: 6577857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
    Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial biotransformations of daunorubicin to aglycones by rat liver microsomes.
    Schwartz HS; Parker NB
    Cancer Res; 1981 Jun; 41(6):2343-8. PubMed ID: 7237433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular pharmacology of amino acid derivatives of daunorubicin and doxorubicin in suspension of renal proximal tubules.
    Hjelle JT; Baurain R; Masquelier M; Trouet A
    J Pharmacol Exp Ther; 1984 May; 229(2):372-80. PubMed ID: 6585548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current status of clinical results of new antitumor drugs].
    Ogawa M
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):179-88. PubMed ID: 3918502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
    Bogush T; Robert J
    Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative models for growth inhibition of human leukemia cells by antitumor anthracycline derivatives.
    Kanter PM; Schwartz HS
    Cancer Res; 1979 Sep; 39(9):3661-72. PubMed ID: 476691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.